Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: Iovance Biotherapeutics Inc. Common Stock and ProShares UltraPro S&P500 are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 2,078,694). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 29 Days on average.
| IOVA | UPRO | |
|---|---|---|
Market Cap | $6.04B | $5.55B |
Volume | 14,805,993 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $14.82 | $157.66 |
52-Week Low | $1.81 | $89.29 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.73, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026.
The outlook is cautiously optimistic due to bullish technical trends, but the absence of fundamental metrics like P/E and ROE increases reliance on market sentiment. Risks include S&P 500 volatility and profit growth concerns highlighted in recent news. Investors should seek updated financials for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
